Cost Benefit Analysis

Cost-effective laparoscopic pyeloplasty: Single center experience

Urology / Treatment Outcome / Adolescent / Humans / Child / Female / Male / Follow-up studies / Cost effectiveness / Clinical Sciences / Middle Aged / Adult / Cost Benefit Analysis / Laparoscopy / Female / Male / Follow-up studies / Cost effectiveness / Clinical Sciences / Middle Aged / Adult / Cost Benefit Analysis / Laparoscopy

Practical Guidelines for Economic Evaluations Alongside Equivalence Trials

Research Methodology / Treatment Outcome / Adolescent / Applied Economics / Humans / Cost Effectiveness Analysis / Depressive Disorder / Cost effectiveness / Middle Aged / Quality adjusted life years / Adult / Public health systems and services research / Economic Models / Cost Benefit Analysis / Economic evaluation / Health Care Costs / Cost Effectiveness Analysis / Depressive Disorder / Cost effectiveness / Middle Aged / Quality adjusted life years / Adult / Public health systems and services research / Economic Models / Cost Benefit Analysis / Economic evaluation / Health Care Costs

Cost-effective trapezoidal modified Boyden chamber with comparable accuracy to a commercial apparatus

Technology / Microfluidics / Flow Cytometry / Cell separation / Ultrafiltration / Biological Sciences / Chemotaxis / Cost Benefit Analysis / Equipment Design / Equipment Failure Analysis / Biological Sciences / Chemotaxis / Cost Benefit Analysis / Equipment Design / Equipment Failure Analysis

Dabigatrón versus acenocumarol para la prevención del ictus en la fibrilación atrial: análisis de impacto presupuestario en un departamento sanitario

Spain / Stroke / Humans / Female / Atrial Fibrillation / Anticoagulants / Aged / Middle Aged / Budgets / Public health systems and services research / Cost Benefit Analysis / Drug Costs / Benzimidazoles / Anticoagulants / Aged / Middle Aged / Budgets / Public health systems and services research / Cost Benefit Analysis / Drug Costs / Benzimidazoles

[Pharmaceutical prescription in primary care. SESPAS report 2012]

Primary Health Care / Quality Control / Spain / Humans / Case Management / Government Agencies / Self medication / Cost Benefit Analysis / Drug Costs / Polypharmacy / Health Priorities / Drug Utilization / Government Agencies / Self medication / Cost Benefit Analysis / Drug Costs / Polypharmacy / Health Priorities / Drug Utilization

Unequal racial access to kidney transplantation

Law / Jurisprudence / Government / Social Justice / Prejudice / Kidney diseases / Resource Allocation / Treatment Outcome / Mortality / Transplantation / Policy making / Renal transplantation / Humans / Kidney / Federal Government / End Stage Renal Disease / United States / Organ Transplantation / Cyclosporine / Medical Care / Organizational Policy / African Americans / Health Care Rationing / Prevalence / Coercion / Kidney Transplant / Success Rate / Major histocompatibility complex / Cost Benefit Analysis / Return to Work / Prognosis / European Continental Ancestry Group / Formal Social Control / Chronic Kidney Failure / Public Policy / Kidney diseases / Resource Allocation / Treatment Outcome / Mortality / Transplantation / Policy making / Renal transplantation / Humans / Kidney / Federal Government / End Stage Renal Disease / United States / Organ Transplantation / Cyclosporine / Medical Care / Organizational Policy / African Americans / Health Care Rationing / Prevalence / Coercion / Kidney Transplant / Success Rate / Major histocompatibility complex / Cost Benefit Analysis / Return to Work / Prognosis / European Continental Ancestry Group / Formal Social Control / Chronic Kidney Failure / Public Policy

Cost-effectiveness: How do we avoid making a difficult science incomprehensible?

Science / Research / Ophthalmic Epidemiology / Humans / Clinical Sciences / Optometry and Ophthalmology / Quality adjusted life years / Public health systems and services research / Cost Benefit Analysis / Optometry and Ophthalmology / Quality adjusted life years / Public health systems and services research / Cost Benefit Analysis

Evaluación económica de rituximab en combinación con fludarabina y ciclofosfamida en comparación con fludarabina y ciclofosfamida en el tratamiento de la leucemia linfática crónica

Spain / Humans / Markov chains / Chronic Lymphocytic Leukemia / Cost effectiveness / Quality adjusted life years / Cost Benefit Analysis / Disease Progression / Health Care Costs / Cyclophosphamide / Monte Carlo Method / Quality adjusted life years / Cost Benefit Analysis / Disease Progression / Health Care Costs / Cyclophosphamide / Monte Carlo Method

Concentrados de plaquetas procedentes de sangre total (buffy coat) u obtenidos por aféresis; ¿qué producto emplear?

Spain / Humans / Blood Safety / Cost effectiveness / Adverse Drug Reaction / Cost Benefit Analysis / Blood Donors / Point of View / Medicina Clinica / Plateletpheresis / Cost Benefit Analysis / Blood Donors / Point of View / Medicina Clinica / Plateletpheresis

Cost-effectiveness: How do we avoid making a difficult science incomprehensible?

Science / Research / Ophthalmic Epidemiology / Humans / Clinical Sciences / Optometry and Ophthalmology / Quality adjusted life years / Public health systems and services research / Cost Benefit Analysis / Optometry and Ophthalmology / Quality adjusted life years / Public health systems and services research / Cost Benefit Analysis

Priorización de intervenciones sanitarias en función de su efectividad: un paso intermedio en el camino hacia una medicina más eficiente

Health Policy / Germany / Humans / United States / Health Care Rationing / Great Britain / Quality adjusted life years / Cost Benefit Analysis / Comparative Effectiveness Research / Health Priorities / Medicina Clinica / Great Britain / Quality adjusted life years / Cost Benefit Analysis / Comparative Effectiveness Research / Health Priorities / Medicina Clinica

Costo-Efectividad del Tratamiento de Salmeterol/Fluticasona en Comparación con Leucotrieno Montelukast para el Control del Asma Infantil

Asthma / Treatment Outcome / Adolescent / Applied Economics / Mexico / Prospective studies / Humans / Child / Hospitalization / Cost effectiveness / Public health systems and services research / Time Factors / Economic Models / Cost Benefit Analysis / Drug Costs / Cost Savings / MEXICO / Quinolines / Prospective studies / Humans / Child / Hospitalization / Cost effectiveness / Public health systems and services research / Time Factors / Economic Models / Cost Benefit Analysis / Drug Costs / Cost Savings / MEXICO / Quinolines

Is laparoscopic colectomy as cost beneficial as open colectomy?

Humans / Female / Male / Clinical Sciences / Aged / Middle Aged / Adult / Cost Benefit Analysis / Laparoscopy / Colectomy / Middle Aged / Adult / Cost Benefit Analysis / Laparoscopy / Colectomy

A randomised clinical trial of a comprehensive exercise program for chronic whiplash: trial protocol

Research Design / Pain / Australia / Quality of life / Treatment Outcome / Exercise therapy / Pain Management / Humans / Human Resources for Health / Health related Quality of Life / Effect size / Health Services / Chronic Disease / Scale / Cost effectiveness / Randomised Controlled Trial / Clinical Sciences / Time Factors / Cost Benefit Analysis / Health Care Costs / Motor Vehicle Accident / Pain Measurement / Exercise therapy / Pain Management / Humans / Human Resources for Health / Health related Quality of Life / Effect size / Health Services / Chronic Disease / Scale / Cost effectiveness / Randomised Controlled Trial / Clinical Sciences / Time Factors / Cost Benefit Analysis / Health Care Costs / Motor Vehicle Accident / Pain Measurement

Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial

Expert testimony / Medical Microbiology / Treatment Outcome / Spain / Decision Trees / Humans / Theoretical Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Viral Load / Humans / Theoretical Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Viral Load
Copyright © 2017 DATOSPDF Inc.